CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy

Group 1 - CVS Health Corporation announced its Q1 2025 earnings, with a positive market response reflected in a share price increase of over 7% [2] - The company provides detailed financial models and research focused on the pharmaceutical, biotech, and healthcare sectors [2] - The investing group Haggerston BioHealth, led by a biotech consultant, offers insights into product sales, forecasts, and market analysis for major pharmaceutical companies [2]